Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 8/20 | 0.44 |
| ▸ | PYGL | P06737 | 3/20 | 0.43 |
| ▸ | PYGM | P11217 | 2/20 | 0.43 |
| ▸ | GBA1 | P04062 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8591408 | 1.00 | PYGB (0.44) | PYGBPYGLPYGMGBA1GAA | |
| SCHEMBL28510346 | 1.00 | PYGB (0.44) | PYGBPYGLPYGMGBA1GAA | |
| SCHEMBL30335844 | 1.00 | PYGB (0.44) | PYGBPYGLPYGMGBA1GAA | |
| SCHEMBL28520844 | 1.00 | PYGB (0.44) | PYGBPYGLPYGMGBA1GAA | |
| SCHEMBL6657589 | 1.00 | PYGB (0.44) | PYGBPYGLPYGMGBA1GAA | |
| Hydrochloric Acid SCHEMBL30833067 | 0.98 | PYGB (0.42) | PYGBPYGLPYGMGBA1GAA | |
| SCHEMBL31520861 | 0.93 | PYGB (0.38) | PYGBPYGLPYGMGBA1GAA | |
| SCHEMBL31520885 | 0.93 | PYGB (0.38) | PYGBPYGLPYGMGBA1GAA | |
| SCHEMBL7134097 | 0.93 | PYGB (0.38) | PYGBPYGLPYGMGBA1GAA | |
| SCHEMBL27920926 | 0.93 | PYGB (0.38) | PYGBPYGLPYGMGBA1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112334582-A | Method for producing protein | 花王株式会社 | 2021-02-05 | — | — | CN | claimed |
| EP-2654732-A1 | COMPRESSED SOLID DOSAGE FORMS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2013-10-30 | — | — | EP | claimed |
| US-20130280325-A1 | COMPRESSED SOLID DOSAGE FORMS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-10-24 | — | — | US | claimed |
| WO-2012085194-A1 | COMPRESSED SOLID DOSAGE FORMS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-06-28 | — | — | WO | claimed |
| EP-2468263-A1 | Compressed solid dosage forms | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2012-06-27 | — | — | EP | claimed |
| US-20040162424-A1 | Method of producing derivatives of lactosamine | NILSSON KURT (SE) | 2004-08-19 | — | — | US | claimed |
| US-6653109-B1 | With a beta 1-4 linkage, by reacting galactose and glycosyl donor with a glucopyranosamino compound in the presence of Bullera singularis or a glycosidase; use to inhibit/modify cell-mediated inflammation | PROCUR AB (SE) | 2003-11-25 | — | — | US | claimed |
| CN-1117872-C | method for producing lactosamine derivatives | BIO FLEXIN AB (SE) | 2003-08-13 | — | — | CN | claimed |
| EP-0839210-B1 | METHOD OF PRODUCING DERIVATIVES OF GLC-BETA 1-4GLC-N-ACETYL | BIOFLEXIN AB (SE) | 2000-10-11 | — | — | EP | claimed |
| US-6077695-A | ECONOMIC PROCESS USING BULLERA SINGULARIS OR COMPOSITION OR LYSATE TO FORM SACCHARIDE FROM DONOR GLUCOSE DERIVATIVE AND ACCEPTOR GLUCOPYRANOSAMINO DERIVATIVE | BIOFLEXIN AB (SE) | 2000-06-20 | — | — | US | claimed |
| EP-0839210-A1 | METHOD OF PRODUCING DERIVATIVES OF GLC-BETA 1-4GLC-N-ACETYL | BIOFLEXIN AB (SE) | 1998-05-06 | — | — | EP | claimed |
| WO-1997003206-A1 | METHOD OF PRODUCING DERIVATIVES OF GLC-BETA 1-4GLC-N-ACETYL | BIOFLEXIN AB (SE) | 1997-01-30 | — | — | WO | claimed |
| WO-2023199881-A1 | METHOD FOR PRODUCING SEMICONDUCTOR SUBSTRATE AND RESIST UNDERLAYER FILM FORMING COMPOSITION | JSR株式会社 | 2023-10-19 | — | — | WO | disclosed |
| CN-109414486-B | Composition for treating and preventing hoof and claw diseases | 伊戈尔.波利亚科夫 | 2023-06-06 | — | — | CN | disclosed |
| CN-115753702-A | Method for rapid preparation of labeled glycosylamines and analysis of glycosylated biomolecules producing said labeled glycosylamines | 沃特世科技公司 | 2023-03-07 | — | — | CN | disclosed |
| CN-115594724-A | Glucosamine derivatives for preventing or treating joint diseases | 润佳（苏州）医药科技有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| WO-1995018864-A1 | METHOD OF PRODUCING DERIVATIVES OF LACTOSAMINE | BIOFLEXIN AB (SE) | 1995-07-13 | — | — | WO | disclosed |
| WO-1995018864-A1 | METHOD OF PRODUCING DERIVATIVES OF LACTOSAMINE | BIOFLEXIN AB (SE) | 1995-07-13 | — | — | WO | disclosed |
| EP-0371408-A2 | Biocatalysts and process for their preparation | CIBA-GEIGY AG (CH) | 1990-06-06 | — | — | EP | disclosed |
| EP-0056458-B1 | NITROSOUREA DERIVATIVES, A PROCESS FOR PREPARING SAME AND THERAPEUTIC COMPOSITIONS | Tanabe Seiyaku Co., Ltd. (JP) | 1985-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162424-A1 | Method of producing derivatives of lactosamine | B3GNT2, ENGASE, FUT6 | PYGB 1741/4885PYGL 808/4885PYGM 1765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.